The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Adjuvant chemotherapy improves 5-year survival after resection of nonsmall cell lung cancer by approximately 10%. Adjuvant therapy is most appropriate for patients with node-positive disease (N1 or N2) or a primary tumor greater than 4 cm. The best available data suggests that the elderly, certainly those between ages 65 and 75, accrue a benefit similar to younger patients, despite inferior dose delivery...
Chemotherapy now has an established role in the treatment of hormone-refractory metastatic prostate cancer. This review summarises the results of the latest trials and discusses ongoing studies investigating the role of chemotherapy earlier in the disease.
Non-small-cell lung cancer (NSCLC) accounts for approximately80% of lung cancers diagnosed worldwide. Surgical resection offers the best chance for cure for those patients diagnosed with early-stage disease; however, the vast majority of patients will eventually relapse. Despite complete surgical resection, recurrences are likely due to undetectable microscopic disease at diagnosis, making these patients...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.